An initiative to improve care and standardize identification, assessment, referrals, and treatment for patients with HCM has been launched by the AHA.

Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS/MAPK ...

Background In hypertrophic cardiomyopathy (HCM), most of the factors associated with the risk of sudden cardiac death (SCD) are also involved in the pathophysiology of exercise limitation. The present ...

Specialized studies for the evaluation of hypertrophic cardiomyopathy Johns Hopkins is a pioneer in the development of cardiac MRI for a variety of conditions including arrhythmias (abnormalities of ...

After hours: January 3 at 4:01:23 PM EST Loading Chart for RMBL ...